Eyegate Pharmaceuticals (EYEG) said Wednesday it has completed its target enrollment of 21 patients in a mid-stage proof-of-concept study of PP-001 for ocular surface inflammation due to ocular surface diseases, including dry eye.
Topline data from the study are expected to be released in Q4, with an investigational new drug filing in the same quarter.
Target : $ 2.9
Topline data from the study are expected to be released in Q4, with an investigational new drug filing in the same quarter.
Target : $ 2.9
Comment:
Shall We Start again ? Hope this is the best time to Climb...